Eli Lilly and Company (LLY) is a publicly traded drug manufacturers-general business based in the US. In the week up to 28 September Eli Lilly and Company shares surged 12.78% to a closing position of $334.38. Over the last 12 months, Eli Lilly and Company's share price has risen by 43.67% from $230.93. Eli Lilly and Company is listed on the NYSE and employs 35,000 staff. All prices are listed in US Dollars.
Best for
0% commission
Best for
Beginner investments
Best for
Mobile app
Best for
Index funds
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|
|
£0 | $10 | £7.32 £1,471.13 total |
Capital at risk |
|
£0 | £250 | £16.19 £1,480.00 total |
Capital at risk |
|
£0 | No minimum | £14.64 £1,478.45 total |
Capital at risk |
 |
£0 | £1 | £26.59 £1,490.40 total |
Capital at risk |
 |
£0 | £0.01 | £1.46 £1,465.28 total |
Capital at risk |
 |
£9.99 per month | No minimum | £29.95 £1,493.76 total |
Capital at risk |
 |
£0 | £50 | £7.32 £1,471.13 total |
Capital at risk |
 |
£36 per year | £20 | £27.80 £1,491.61 total |
Capital at risk |
Full comparison of share dealing platforms
Historical closes compared with the last close of $331.78
| 1 week (2022-09-29) | 0.54% |
|---|---|
| 1 month (2022-09-06) | 8.14% |
| 3 months (2022-07-06) | 0.49% |
| 6 months (2022-04-06) | 8.48% |
| 1 year (2021-10-04) | 47.56% |
|---|---|
| 2 years (2020-10-06) | 130.19% |
| 3 years (2019-10-04) | 206.64% |
| 5 years (2017-10-06) | 281.01% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, Eli Lilly and Company shares trade at around 42x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9582. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $10.4 billion (£9.2 billion).
The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure a its profitability.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.
Eli Lilly and Company's total ESG risk: 32.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 01/01/2019) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Eli Lilly and Company's environmental score: 0.63/100
Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Eli Lilly and Company's social score: 16.68/100
Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Eli Lilly and Company's governance score: 13.31/100
Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Eli Lilly and Company's controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.
Eli Lilly and Company was last rated for ESG on: 2019-01-01.
| Total ESG score | 32.36 |
|---|---|
| Total ESG percentile | 70.22 |
| Environmental score | 0.63 |
| Environmental score percentile | 1 |
| Social score | 16.68 |
| Social score percentile | 1 |
| Governance score | 13.31 |
| Governance score percentile | 1 |
| Level of controversy | 3 |
| Open | $328.3 |
|---|---|
| High | $333.85 |
| Low | $327.52 |
| Close | $331.78 |
| Previous close | $329.89 |
| Change | $1.89 |
| Change % | 0.5729% |
| Volume | 2,112,582 |
| 52-week range | $221.1015 - $341.7 |
|---|---|
| 50-day moving average | $314.16 |
| 200-day moving average | $290.2329 |
| Wall St. target price | $304.28 |
| PE ratio | 42.3116 |
| Dividend yield | $3.66 (1.11%) |
| Earnings per share (TTM) | $6.2666 |
Dividend yield: 1.11% of stock value
Forward annual dividend yield: 1.26% of stock value
Dividend payout ratio: 45.66% of net profits
Eli Lilly and Company has recently paid out dividends equivalent to 1.11% of its share value annually.
Eli Lilly and Company has paid out, on average, around 45.66% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.26% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 1.26% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $3.66 per share.
While Eli Lilly and Company's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.
Eli Lilly and Company's most recent dividend payout was on 9 September 2022. The latest dividend was paid out to all shareholders who bought their shares by 12 August 2022 (the "ex-dividend date").
Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as $221.1015 up to $341.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.3775. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ever wondered how to buy shares in Veru? We explain how and compare a range of providers that can give you access to many brands, including Veru.
Ever wondered how to buy shares in C4 Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including C4 Therapeutics.
Ever wondered how to buy shares in Clever Leaves? We explain how and compare a range of providers that can give you access to many brands, including Clever Leaves.
Mental health stocks can be rewarding, but there are risks involved that could impact your profits. Find out how to invest in companies in the mental health industry.
Pharma stocks can be rewarding, but there are risks involved that could impact your profits. Find out the best way to invest in pharma stock.
Ever wondered how to buy shares in Bone Biologics? We explain how and compare a range of providers that can give you access to many brands, including Bone Biologics.
Ever wondered how to buy shares in Adagio Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Adagio.
Ever wondered how to buy shares in Bolt Biotherapeutics? We explain how and compare a range of providers that can give you access to many brands, including Bolt Biotherapeutics.
Ever wondered how to buy shares in Vallon Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Vallon Pharmaceuticals.
Ever wondered how to buy shares in Qualigen Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Qualigen.
